[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,640 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lung cancer immunotherapy: progress, pitfalls, and promises.
Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, Mukherjee A, Paul MK. Lahiri A, et al. Among authors: singh n. Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y. Mol Cancer. 2023. PMID: 36810079 Free PMC article. Review.
Rationale and Design of PEMVITASTART-An Open-label Randomized Trial Comparing Simultaneous Versus Standard Initiation of Vitamin B12 and Folate Supplementation in Nonsquamous, Non-Small-cell Lung Cancer Patients Undergoing First-line Pemetrexed-based Chemotherapy.
Baldi M, Behera D, Kaur J, Kapoor R, Singh N. Baldi M, et al. Among authors: singh n. Clin Lung Cancer. 2017 Jul;18(4):432-435. doi: 10.1016/j.cllc.2016.11.017. Epub 2016 Dec 2. Clin Lung Cancer. 2017. PMID: 28073680 Clinical Trial.
Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
Singh N, Baldi M, Kaur J, Muthu V, Prasad KT, Behera D, Bal A, Gupta N, Kapoor R. Singh N, et al. Cancer. 2019 Jul 1;125(13):2203-2212. doi: 10.1002/cncr.32028. Epub 2019 Mar 2. Cancer. 2019. PMID: 30825389 Free article. Clinical Trial.
Environmental and occupational determinants of lung cancer.
Shankar A, Dubey A, Saini D, Singh M, Prasad CP, Roy S, Bharati SJ, Rinki M, Singh N, Seth T, Khanna M, Sethi N, Kumar S, Sirohi B, Mohan A, Guleria R, Rath GK. Shankar A, et al. Among authors: singh n, singh m. Transl Lung Cancer Res. 2019 May;8(Suppl 1):S31-S49. doi: 10.21037/tlcr.2019.03.05. Transl Lung Cancer Res. 2019. PMID: 31211104 Free PMC article. Review.
Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A, Batra U, Prasad KT, Dabkara D, Ghosh J, Sharma M, Singh N, Suresh P, Jain P, Malik PS, Choudhary P, Ganguly S, Khurana S, Ms S, Bothra S, Muthu V, Biswas B. Patel A, et al. Among authors: singh n. Curr Probl Cancer. 2020 Jun;44(3):100571. doi: 10.1016/j.currproblcancer.2020.100571. Epub 2020 Mar 17. Curr Probl Cancer. 2020. PMID: 32234264
11,640 results
You have reached the last available page of results. Please see the User Guide for more information.